epocrates logo
epocrates logo
epocrates logo
  • 0

Journal Article Synopsis

N Engl J Med

ObesityWeek 2026: Semaglutide delivers substantial weight loss in children with obesity

November 17, 2026

card-image

Clinical takeaway: Consider obesity as a treatable chronic disease even in younger children. In this phase 3 trial, semaglutide plus lifestyle intervention produced substantial BMI reductions and enabled many children to no longer meet criteria for obesity, supporting earlier identification and referral for intensive obesity management.

Childhood obesity affects more than 200 million school-age children worldwide and is associated with early cardiometabolic complications, psychosocial effects, and increased long-term health risks. Treatment options for children younger than 12 years remain limited, with no approved pharmacologic therapies for obesity in this age group.

In the phase 3 STEP Young trial, 167 children aged 6 to under 12 years with obesity were randomized to once-weekly semaglutide or placebo, both alongside lifestyle counseling. At week 68, BMI decreased by 13.5% with semaglutide compared with a 2.7% increase with placebo, representing a 16.2 percentage point difference between groups.

A lower BMI category was achieved by 79% of semaglutide-treated children versus 23% of those receiving placebo. Notably, 38% of children receiving semaglutide no longer met criteria for obesity at week 68, compared with 2% receiving placebo.

Benefits persisted through 104 weeks, with improvements also observed in waist circumference, glycated hemoglobin, triglycerides, and other cardiometabolic measures. Among children with prediabetes at baseline, 93% reverted to normoglycemia by week 68 with semaglutide versus 56% with placebo.

Safety findings were generally consistent with the established GLP-1 receptor agonist profile. Gastrointestinal adverse events were common, including vomiting, diarrhea, and nausea, but most were mild to moderate, and only 4% of semaglutide-treated participants discontinued therapy because of adverse events.

The double-blind, placebo-controlled trial enrolled children aged 6 to <12 years with obesity across 48 sites in nine countries. Participants were randomized 2:1 to semaglutide or placebo for 104 weeks; the primary outcome was percent change in BMI from baseline to week 68.

These findings, presented at ObesityWeek 2026, extend the benefits previously observed in adolescents and may support regulatory review of semaglutide for younger children with obesity. Longer-term follow-up will help clarify effects on growth, cardiometabolic health, and treatment durability.

Source: Jastreboff AM, et al. (2026 Nov 16) N Engl J Med. Semaglutide for the Treatment of Obesity in Children 6 to <12 Years of Age

learn more about epocrates plus

Clinical FAQs

Check out the answers to frequently asked questions about our clinical content.

Download Epocrates from the App StoreDownload Epocrates from the Play Store
About UsFeaturesBusiness SolutionsHelp & FeedbackCookie Preferences
© 2026 epocrates, Inc.   Terms of UsePrivacy PolicyEditorial PolicyDo Not Sell or Share My Information